822 related articles for article (PubMed ID: 26847547)
1. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH).
Nati M; Haddad D; Birkenfeld AL; Koch CA; Chavakis T; Chatzigeorgiou A
Rev Endocr Metab Disord; 2016 Mar; 17(1):29-39. PubMed ID: 26847547
[TBL] [Abstract][Full Text] [Related]
2. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
3. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis.
Chackelevicius CM; Gambaro SE; Tiribelli C; Rosso N
World J Gastroenterol; 2016 Nov; 22(41):9096-9103. PubMed ID: 27895397
[TBL] [Abstract][Full Text] [Related]
4. Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis.
Chen Y; Tian Z
Front Immunol; 2020; 11():1500. PubMed ID: 32765518
[TBL] [Abstract][Full Text] [Related]
5. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update.
Sutti S; Bruzzì S; Albano E
Expert Rev Gastroenterol Hepatol; 2016; 10(2):243-53. PubMed ID: 26634783
[TBL] [Abstract][Full Text] [Related]
6. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Hirsova P; Bamidele AO; Wang H; Povero D; Revelo XS
Front Endocrinol (Lausanne); 2021; 12():760860. PubMed ID: 34777255
[TBL] [Abstract][Full Text] [Related]
7. The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity.
Van Herck MA; Weyler J; Kwanten WJ; Dirinck EL; De Winter BY; Francque SM; Vonghia L
Front Immunol; 2019; 10():82. PubMed ID: 30787925
[TBL] [Abstract][Full Text] [Related]
8. The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease.
Nati M; Chung KJ; Chavakis T
J Innate Immun; 2022; 14(1):31-41. PubMed ID: 34515137
[TBL] [Abstract][Full Text] [Related]
9. Treating inflammation to combat non-alcoholic fatty liver disease.
Wiering L; Tacke F
J Endocrinol; 2023 Jan; 256(1):. PubMed ID: 36259984
[TBL] [Abstract][Full Text] [Related]
10. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression.
Dallio M; Sangineto M; Romeo M; Villani R; Romano AD; Loguercio C; Serviddio G; Federico A
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33406763
[TBL] [Abstract][Full Text] [Related]
11. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease.
Katsarou A; Moustakas II; Pyrina I; Lembessis P; Koutsilieris M; Chatzigeorgiou A
World J Gastroenterol; 2020 May; 26(17):1993-2011. PubMed ID: 32536770
[TBL] [Abstract][Full Text] [Related]
12. Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β.
Hart KM; Fabre T; Sciurba JC; Gieseck RL; Borthwick LA; Vannella KM; Acciani TH; de Queiroz Prado R; Thompson RW; White S; Soucy G; Bilodeau M; Ramalingam TR; Arron JR; Shoukry NH; Wynn TA
Sci Transl Med; 2017 Jun; 9(396):. PubMed ID: 28659437
[TBL] [Abstract][Full Text] [Related]
13. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies.
Luci C; Bourinet M; Leclère PS; Anty R; Gual P
Front Endocrinol (Lausanne); 2020; 11():597648. PubMed ID: 33384662
[TBL] [Abstract][Full Text] [Related]
14. Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis.
Houben T; Brandsma E; Walenbergh SMA; Hofker MH; Shiri-Sverdlov R
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Apr; 1862(4):416-429. PubMed ID: 27472963
[TBL] [Abstract][Full Text] [Related]
15. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
16. Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling.
Barrow F; Khan S; Fredrickson G; Wang H; Dietsche K; Parthiban P; Robert S; Kaiser T; Winer S; Herman A; Adeyi O; Mouzaki M; Khoruts A; Hogquist KA; Staley C; Winer DA; Revelo XS
Hepatology; 2021 Aug; 74(2):704-722. PubMed ID: 33609303
[TBL] [Abstract][Full Text] [Related]
17. Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease.
Martínez-Chantar ML; Delgado TC; Beraza N
Front Immunol; 2021; 12():640869. PubMed ID: 33679803
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease.
Carranza-Trejo AM; Vetvicka V; Vistejnova L; Kralickova M; Montufar EB
Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):783-796. PubMed ID: 33557653
[No Abstract] [Full Text] [Related]
19. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
20. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin.
Ni Y; Nagashimada M; Zhan L; Nagata N; Kobori M; Sugiura M; Ogawa K; Kaneko S; Ota T
Endocrinology; 2015 Mar; 156(3):987-99. PubMed ID: 25562616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
